Each one of us has a genetic blueprint — an ‘instruction manual’ that makes us uniquely human and determines our individual characteristics. Small errors in this blueprint, otherwise known as genetic mutations, can result in a wide range of genetic diseases. Given we inherit our genetic blueprint from our parents, these genetic mutations and diseases may be passed on from parent to child.
PGT-M involves taking a biopsy of the embryo (5–7 cells from the outer layer) after it has grown and developed for 5–6 days. From this sample, we can analyse the genetic material of the embryo and determine whether a genetic mutation is present in the DNA or not. In doing so, we can prevent the transfer of embryos that have the genetic mutation.
PGT-M does carry some risks, including:
Embryos are fragile, so any procedure that involves handling the embryo and disturbing its surrounding conditions poses the risk of harm. However, while the risk of harm will always exist, it is thought that the overall risk of damage to the embryo is minimal.
When we conduct testing on a sample of cells from the embryo, we are assuming that this sample is representative of all the cells in the embryo. However, a condition called mosaicism may exist, where some of the embryo’s cells have the genetic mutation and some of the cells do not. Testing of embryos that display mosaicism can result in an inaccurate or unclear test result.
The results of the genetic testing may return as ‘indeterminant’, meaning the test could not determine whether the genetic material of the embryo was normal, or abnormal. This may occur for a variety of reasons, including a poor-quality embryo.
We may recommend PGT-M when a genetic disease, such as haemophilia, thalassaemia and cystic fibrosis, runs in the family and it has been determined that the offspring could be severely affected. This may be determined with the help of a genetic counsellor and geneticist. Feasibility testing is also required prior to PGT-M to see if your particular genetic condition and variant can be tested for. Your Newlife IVF fertility specialist will assess the specifics of your situation with you and make a recommendation accordingly.
At Newlife IVF, PGT currently costs $699 per embryo.* Feasibility testing costs $1800.
*Fees correct as of 24 February 2021; reduced rates may apply depending on eligibility (in line with new Medicare rebates effective 1 November 2021), as well as number of embryos tested. For PGT pricing specific to your circumstances, please contact us.
Newlife IVF fertility specialist, Dr Nicole Hope, discusses what you can do to boost your chances of falling pregnant in 2022.Learn more
Dr Tiki Osianlis discusses the reasons why an embryo might stop developing, including chromosomal errors and cell division errors.Learn more
Dr Hugo Fernandes discusses genetic screening options during IVF, including carrier screening and preimplantation genetic screening.Learn more